
News|Articles|September 17, 2026
Q&A: Inside the NDC-12 Transition
Author(s)Liberty Dewey, Stephen Appezzato
Liberty Dewey of Cardinal Health breaks down the NDC-12 transition timeline, the four work streams driving it and why the biggest risk sits in trading partner handoffs.
Advertisement
Advertisement
FDA's shift from a 10-digit to a 12-digit National Drug Code carries a longer runway than its headline date suggests. The final rule was published March 5, 2026, but the effective date isn't until March 7, 2033, and the labeling transition that follows doesn't close until March 7, 2036, meaning trading partners will need systems that can handle three NDC formats at once for years.
Related to this article

In the final installment of his interview with Pharmaceutical Commerce, Cencora's Ameer Ali outlines how supply chain stakeholders should prepare systems, processes and trading partners for the shift to NDC-12.

In the final installment of his interview with Pharmaceutical Commerce, Cencora's Gregg Gorniak looks back at DSCSA's five-year evolution and where serialized data is creating value beyond compliance.

Gregg Gorniak explains how AI, RFID and serialized data are helping trading partners move DSCSA compliance from a regulatory checkbox to a source of shared operational value.

At LogiPharma USA 2026, quality leaders explained why connected data, risk-based prioritization, and human accountability must come before AI in supply chain compliance.

Swisslog's Mark Beers discusses how software helps pharma supply chains adapt to shifting portfolios, strengthen inventory verification and build trust.

At LogiPharma USA 2026, leaders from J&J, Sun Pharma, Accord Healthcare, and Freehand discussed visibility, redundancy tradeoffs, and AI's role in resilient pharma supply chains.

McKesson's Chris Van Norman previews his LogiPharma USA keynote on demand signal sharing, AI, and precision distribution for targeted therapies.
Advertisement
Advertisement

